Management and Prevention of HIV Among Transgender Adults

Overview

Journal Top Antivir Med

Specialties Infectious Diseases
Microbiology

Date 2021 Jun 9

PMID 34107207

Citations 1

Authors

Asa E Radix

Affiliations

Soon will be listed here.

Abstract

Transgender individuals face discrimination, violence, social exclusion, and other social, political, and economic factors that result in increased vulnerability to HIV. Rates of viral suppression and uptake of preexposure prophylaxis are lower among transgender individuals than the general population. HIV clinics can help improve these rates by promoting inclusivity and tailoring care to the specific needs of transgender patients. This article summarizes an International Antiviral Society-USA (IAS-USA) webinar presented by Asa E. Radix, MD, PhD, MPH, on August 18, 2020. This webinar is available on demand at https://www.iasusa.org/courses/on-demand-webinar-2020-radix/.

Citing Articles

Rapid or Immediate ART, HIV Stigma, Medical Mistrust, and Retention in Care: An Exploratory Mixed Methods Pilot Study.

Mgbako O, Loughran C, Mathu R, Castor D, McLean J, Sobieszczyk M AIDS Behav. 2023; 27(10):3430-3446.

PMID: 37071333 PMC: 10111080. DOI: 10.1007/s10461-023-04058-4.

References

Meerwijk E, Sevelius J . Transgender Population Size in the United States: a Meta-Regression of Population-Based Probability Samples. Am J Public Health. 2017; 107(2):e1-e8. PMC: 5227946. DOI: 10.2105/AJPH.2016.303578. View

Wilson E, Turner C, Arayasirikul S, Woods T, Tryon J, Franza K . HIV Care Engagement Among Trans Women of Color in San Francisco Bay Area Demonstration Projects: Findings from the Brandy Martell Project and TransAccess. AIDS Behav. 2019; 25(Suppl 1):31-39. DOI: 10.1007/s10461-019-02697-0. View

Shieh E, Marzinke M, Fuchs E, Hamlin A, Bakshi R, Aung W . Transgender women on oral HIV pre-exposure prophylaxis have significantly lower tenofovir and emtricitabine concentrations when also taking oestrogen when compared to cisgender men. J Int AIDS Soc. 2019; 22(11):e25405. PMC: 6832671. DOI: 10.1002/jia2.25405. View

Mehrotra M, Westreich D, McMahan V, Glymour M, Geng E, Grant R . Baseline Characteristics Explain Differences in Effectiveness of Randomization to Daily Oral TDF/FTC PrEP Between Transgender Women and Cisgender Men Who Have Sex With Men in the iPrEx Trial. J Acquir Immune Defic Syndr. 2019; 81(3):e94-e98. PMC: 6578589. DOI: 10.1097/QAI.0000000000002037. View

Woodring J, Kruszon-Moran D, McQuillan G . HIV Infection in U.S. Household Population Aged 18-59: Data From the National Health and Nutrition Examination Survey, 2007-2012. Natl Health Stat Report. 2015; (83):1-13. View

Sevelius J, Carrico A, Johnson M . Antiretroviral therapy adherence among transgender women living with HIV. J Assoc Nurses AIDS Care. 2010; 21(3):256-64. PMC: 2859994. DOI: 10.1016/j.jana.2010.01.005. View

Hirshfield S, Contreras J, Luebe R, Swartz J, Scheinmann R, Reback C . Engagement in HIV Care Among New York City Transgender Women of Color: Findings from the Peer-Led, TWEET Intervention, a SPNS Trans Women of Color Initiative. AIDS Behav. 2019; 25(Suppl 1):20-30. PMC: 7679049. DOI: 10.1007/s10461-019-02667-6. View

Kann L, McManus T, Harris W, Shanklin S, Flint K, Queen B . Youth Risk Behavior Surveillance - United States, 2017. MMWR Surveill Summ. 2018; 67(8):1-114. PMC: 6002027. DOI: 10.15585/mmwr.ss6708a1. View

Sevelius J, Saberi P, Johnson M . Correlates of antiretroviral adherence and viral load among transgender women living with HIV. AIDS Care. 2014; 26(8):976-82. PMC: 4054817. DOI: 10.1080/09540121.2014.896451. View

10.

Wood S, Lee S, Barg F, Castillo M, Dowshen N . Young Transgender Women's Attitudes Toward HIV Pre-exposure Prophylaxis. J Adolesc Health. 2017; 60(5):549-555. PMC: 5401785. DOI: 10.1016/j.jadohealth.2016.12.004. View

11.

Grant R, Lama J, Anderson P, McMahan V, Liu A, Vargas L . Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010; 363(27):2587-99. PMC: 3079639. DOI: 10.1056/NEJMoa1011205. View

12.

Restar A, Kuhns L, Reisner S, Ogunbajo A, Garofalo R, Mimiaga M . Acceptability of Antiretroviral Pre-exposure Prophylaxis from a Cohort of Sexually Experienced Young Transgender Women in Two U.S. Cities. AIDS Behav. 2018; 22(11):3649-3657. PMC: 6204093. DOI: 10.1007/s10461-018-2127-0. View

13.

Sevelius J, Chakravarty D, Neilands T, Keatley J, Shade S, Johnson M . Evidence for the Model of Gender Affirmation: The Role of Gender Affirmation and Healthcare Empowerment in Viral Suppression Among Transgender Women of Color Living with HIV. AIDS Behav. 2019; 25(Suppl 1):64-71. PMC: 9351439. DOI: 10.1007/s10461-019-02544-2. View

14.

Wirtz A, Poteat T, Radix A, Althoff K, Cannon C, Wawrzyniak A . American Cohort to Study HIV Acquisition Among Transgender Women in High-Risk Areas (The LITE Study): Protocol for a Multisite Prospective Cohort Study in the Eastern and Southern United States. JMIR Res Protoc. 2019; 8(10):e14704. PMC: 6802485. DOI: 10.2196/14704. View

15.

Johns M, Lowry R, Andrzejewski J, Barrios L, Demissie Z, McManus T . Transgender Identity and Experiences of Violence Victimization, Substance Use, Suicide Risk, and Sexual Risk Behaviors Among High School Students - 19 States and Large Urban School Districts, 2017. MMWR Morb Mortal Wkly Rep. 2019; 68(3):67-71. PMC: 6348759. DOI: 10.15585/mmwr.mm6803a3. View

16.

Golub S, Fikslin R, Starbuck L, Klein A . High Rates of PrEP Eligibility but Low Rates of PrEP Access Among a National Sample of Transmasculine Individuals. J Acquir Immune Defic Syndr. 2019; 82(1):e1-e7. PMC: 6692190. DOI: 10.1097/QAI.0000000000002116. View

17.

Reback C, Kisler K, Fletcher J . A Novel Adaptation of Peer Health Navigation and Contingency Management for Advancement Along the HIV Care Continuum Among Transgender Women of Color. AIDS Behav. 2019; 25(Suppl 1):40-51. PMC: 6904539. DOI: 10.1007/s10461-019-02554-0. View

18.

Hiransuthikul A, Janamnuaysook R, Himmad K, Kerr S, Thammajaruk N, Pankam T . Drug-drug interactions between feminizing hormone therapy and pre-exposure prophylaxis among transgender women: the iFACT study. J Int AIDS Soc. 2019; 22(7):e25338. PMC: 6625338. DOI: 10.1002/jia2.25338. View

19.

Bockting W, MacCrate C, Israel H, Mantell J, Remien R . Engagement and Retention in HIV Care for Transgender Women: Perspectives of Medical and Social Service Providers in New York City. AIDS Patient Care STDS. 2019; 34(1):16-26. PMC: 6983737. DOI: 10.1089/apc.2019.0067. View

20.

Cottrell M, Prince H, Schauer A, Sykes C, Maffuid K, Poliseno A . Decreased Tenofovir Diphosphate Concentrations in a Transgender Female Cohort: Implications for Human Immunodeficiency Virus Preexposure Prophylaxis. Clin Infect Dis. 2019; 69(12):2201-2204. PMC: 7188232. DOI: 10.1093/cid/ciz290. View